<!DOCTYPE html >
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p52" style="overflow: hidden; position: relative; width: 935px; height: 1210px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_52{left:110px;top:1133px;letter-spacing:-0.1px;word-spacing:0.2px;}
#t2_52{left:459px;top:1133px;letter-spacing:0.3px;}
#t3_52{left:757px;top:1133px;word-spacing:-0.7px;}
#t4_52{left:220px;top:109px;letter-spacing:-0.1px;word-spacing:-0.3px;}
#t5_52{left:275px;top:131px;letter-spacing:-0.1px;word-spacing:0.2px;}
#t6_52{left:220px;top:153px;letter-spacing:-0.1px;}
#t7_52{left:220px;top:175px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t8_52{left:275px;top:197px;}
#t9_52{left:220px;top:220px;letter-spacing:-0.1px;}
#ta_52{left:220px;top:242px;word-spacing:-0.3px;}
#tb_52{left:220px;top:264px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tc_52{left:220px;top:286px;letter-spacing:-0.1px;word-spacing:0.1px;}
#td_52{left:275px;top:308px;}
#te_52{left:220px;top:330px;letter-spacing:-0.1px;}
#tf_52{left:220px;top:352px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tg_52{left:275px;top:375px;}
#th_52{left:220px;top:397px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#ti_52{left:220px;top:419px;letter-spacing:-0.1px;}
#tj_52{left:220px;top:441px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tk_52{left:220px;top:463px;letter-spacing:-0.1px;}
#tl_52{left:220px;top:485px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tm_52{left:220px;top:507px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tn_52{left:220px;top:529px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#to_52{left:220px;top:552px;letter-spacing:-0.1px;}
#tp_52{left:220px;top:574px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tq_52{left:220px;top:596px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tr_52{left:220px;top:618px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#ts_52{left:220px;top:640px;letter-spacing:-0.1px;}
#tt_52{left:220px;top:662px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tu_52{left:220px;top:684px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tv_52{left:220px;top:706px;letter-spacing:-0.1px;}
#tw_52{left:220px;top:729px;letter-spacing:-0.1px;}
#tx_52{left:220px;top:751px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#ty_52{left:220px;top:773px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tz_52{left:220px;top:795px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#t10_52{left:220px;top:817px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#t11_52{left:220px;top:839px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t12_52{left:220px;top:862px;letter-spacing:-0.1px;}
#t13_52{left:220px;top:884px;letter-spacing:-0.1px;word-spacing:-0.3px;}
#t14_52{left:220px;top:906px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#t15_52{left:220px;top:928px;letter-spacing:-0.1px;word-spacing:-0.3px;}
#t16_52{left:220px;top:950px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t17_52{left:220px;top:972px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#t18_52{left:220px;top:994px;letter-spacing:-0.1px;}
#t19_52{left:220px;top:1016px;letter-spacing:-0.1px;word-spacing:-0.3px;}
#t1a_52{left:220px;top:1039px;letter-spacing:-0.1px;}
#t1b_52{left:220px;top:1061px;letter-spacing:-0.1px;word-spacing:-0.2px;}

.s1_52{
	FONT-SIZE: 67.5px;
	FONT-FAMILY: Calibri_f8x;
	color: rgb(0,0,0);
}

</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts52" type="text/css" >

@font-face {
	font-family: Calibri_f8x;
	src: url("fonts/Calibri_f8x.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg52Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg52" style="-webkit-user-select: none;"><object width="935" height="1210" data="52/52.svg" type="image/svg+xml" id="pdf52" style="width:935px; height:1210px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div id="t1_52" class="t s1_52">Medicare FFS Claims (Version K) Codebook</div>
<div id="t2_52" class="t s1_52">49</div>
<div id="t3_52" class="t s1_52">May 2017</div>
<div id="t4_52" class="t s1_52">7010 = Morphine sulfate concentrate (preservative free) per 10 mg (eligible for pass-</div>
<div id="t5_52" class="t s1_52">through payments) </div>
<div id="t6_52" class="t s1_52">7011 = Oprelevekin, inj, 5 mg (eligible for pass-through payments) </div>
<div id="t7_52" class="t s1_52">7012 = Pentamidine isethionate, 300 mg (eligible for pass-through payments) (obsolete </div>
<div id="t8_52" class="t s1_52">1/01) </div>
<div id="t9_52" class="t s1_52">7014 = Fentanyl citrate, inj, up to 2 ml (eligible for pass-through payments) </div>
<div id="ta_52" class="t s1_52">7015 = Busulfan, oral 2 mg (eligible for pass-through payments) </div>
<div id="tb_52" class="t s1_52">7019 = Aprotinin, 10,000 kiu (eligible for pass-through payments) </div>
<div id="tc_52" class="t s1_52">7021 = Baclofen, intrathecal, 50 mcg (eligible for pass-through payments) (obsolete </div>
<div id="td_52" class="t s1_52">1/01) </div>
<div id="te_52" class="t s1_52">7022 = Elliotts B Solution, per ml (eligible for pass-through payments) </div>
<div id="tf_52" class="t s1_52">7023 = Treatment for bladder calculi, I.e. Renacidin per 500 ml (eligible for pass-through </div>
<div id="tg_52" class="t s1_52">payments) </div>
<div id="th_52" class="t s1_52">7024 = Corticorelin ovine triflutate, 0.1 mg (eligible for pass-through payments) </div>
<div id="ti_52" class="t s1_52">7025 = Digoxin immune FAB (Ovine), 10 mg (eligible for pass-through payments) </div>
<div id="tj_52" class="t s1_52">7026 = Ethanolamine oleate, 1000 ml (eligible for pass-through payments) </div>
<div id="tk_52" class="t s1_52">7027 = Fomepizole, 1.5 G (eligible for pass-through payments) </div>
<div id="tl_52" class="t s1_52">7028 = Fosphenytoin, 50 mg (eligible for pass-through payments) </div>
<div id="tm_52" class="t s1_52">7029 = Glatiramer acetate, 25 mg (eligible for pass-through payments) </div>
<div id="tn_52" class="t s1_52">7030 = Hemin, 1 mg (eligible for pass-through payments) </div>
<div id="to_52" class="t s1_52">7031 = Octreotide Acetate, 500 mcg (eligible for pass-through payments) </div>
<div id="tp_52" class="t s1_52">7032 = Sermorelin acetate, 0.5 mg (eligible for pass-through payments) </div>
<div id="tq_52" class="t s1_52">7033 = Somatrem, 5 mg (eligible for pass-through payments) </div>
<div id="tr_52" class="t s1_52">7034 = Somatropin, 1 mg (eligible for pass-through payments) </div>
<div id="ts_52" class="t s1_52">7035 = Teniposide, 50 mg (eligible for pass-through payments) </div>
<div id="tt_52" class="t s1_52">7036 = Urokinase, inj, IV, 250,000 I.U. (not subject to national coinsurance) </div>
<div id="tu_52" class="t s1_52">7037 = Urofollitropin, 75 I.U. (eligible for pass-through payments) </div>
<div id="tv_52" class="t s1_52">7038 = Muromonab-CD3, 5 mg (eligible for pass-through payments) </div>
<div id="tw_52" class="t s1_52">7039 = Pegademase bovine inj 25 I.U. (eligible for pass-through payments) </div>
<div id="tx_52" class="t s1_52">7040 = Pentastarch 10% inj, 100 ml (eligible for pass-through payments) </div>
<div id="ty_52" class="t s1_52">7041 = Tirofiban HCL, 0.5 mg (not subject to national coinsurance) </div>
<div id="tz_52" class="t s1_52">7042 = Capecitabine, oral 150 mg (eligible for pass-through payments) </div>
<div id="t10_52" class="t s1_52">7043 = Infliximab, 10 MG (eligible for pass-through payments) </div>
<div id="t11_52" class="t s1_52">7045 = Trimetrexate Glucoronate (eligible for pass-through payments) </div>
<div id="t12_52" class="t s1_52">7046 = Doxorubicin Hcl Liposome (eligible for pass-through payments) </div>
<div id="t13_52" class="t s1_52">7047 = Droperidol/fentanyl inj (eff. 1/01) </div>
<div id="t14_52" class="t s1_52">7048 = Alteplase, 1 mg (eff. 1/01) </div>
<div id="t15_52" class="t s1_52">7049 = Filgrastim 480 mcg injection (eff. 1/01) </div>
<div id="t16_52" class="t s1_52">7315 = Sodium hyaluronate, 20 mg (eff. 1/01) </div>
<div id="t17_52" class="t s1_52">8099 = Spectranetics Lead Lock Dev (eff. 1/01) (obsolete 4/01) </div>
<div id="t18_52" class="t s1_52">8100 = Adhesion barrier, ADCON-L (eff. 1/01) (obsolete 4/01) </div>
<div id="t19_52" class="t s1_52">8102 = SurgiVision Esoph Coil (eff. 1/01) (obsolete 4/01) </div>
<div id="t1a_52" class="t s1_52">9000 = Na chromate Cr51, per 0.25mCi (eff. 1/01) </div>
<div id="t1b_52" class="t s1_52">9001 = Linezolid inj, 200mg (eff. 1/01) </div>

<!-- End text definitions -->


</div>
</body>
</html>
